{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:55:45Z","timestamp":1763348145606,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clml.2018.08.012","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T22:54:08Z","timestamp":1536706448000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP)"],"prefix":"10.1016","volume":"19","author":[{"given":"Francesco","family":"Gaudio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pisapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Carluccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.08.012_bib1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.012_bib2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.012_bib3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem cell transplantation for Hodgkin\u2019s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas\/Transplante Autologo de Medula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib4","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.1999.17.10.3101","article-title":"High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin\u2019s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation","volume":"17","author":"Sweetenham","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin\u2019s disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib6","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","article-title":"Long-term results of blood and marrow transplantation for Hodgkin\u2019s lymphoma","volume":"19","author":"Akpek","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.08.012_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hogkin\u2019s disease","volume":"14","author":"Milpied","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.012_bib11","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib12","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.012_bib13","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","article-title":"Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s disease: low transplant-related mortality and impact of intensity of conditioning regimen","volume":"35","author":"Anderlini","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.08.012_bib14","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus lymphoma effect after reduced intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.012_bib15","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2002.11.088","article-title":"Role of non-myeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies","volume":"20","author":"Branson","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Non-myeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin\u2019s lymphoma: results of a Spanish Prospective Cooperative Protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2018.08.012_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib19","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib20","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.012_bib21","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"22","author":"Brown","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.012_bib22","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018305780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018305780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:26Z","timestamp":1761870746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018305780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2152265018305780"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}